Tasquinimod also reduced the accumulation of MDSC in a castration-resistant, syngeneic transplantable murine prostate cancer model (CR Myc-Cap) and enhanced the survivin cancer vaccine efficacy in this model [42]. The gene discussed is BIRC5; the disease is cancer.